Q-omics provides the consensus-scored ZNF324B profile across patient tissues and cancer cell-line models. ZNF324B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF324B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF324B RNA expression shows 19,549 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where ZNF324B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF324B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF324B survival associations across molecular data types. ZNF324B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF324B RNA expression–survival associations across cancer types. High ZNF324B expression shows unfavorable associations in MESO, LGG and ACC, but favorable associations in HNSC, KIRC and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF324B RNA expression.
This table summarizes ZNF324B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF324B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF324B shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, COAD, STAD and BLCA. The HNSC box plot shows higher ZNF324B RNA expression in tumor versus normal tissue (log2 FC = +0.395, t-test p < 0.001).
This table shows molecular features associated with ZNF324B in patient tissues and cancer cell lines. In patient samples, ZNF324B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF324B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
